Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05168969
Other study ID # 21CH164
Secondary ID ANSM
Status Completed
Phase
First received
Last updated
Start date July 2, 2022
Est. completion date December 10, 2022

Study information

Verified date April 2023
Source Centre Hospitalier Universitaire de Saint Etienne
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A few years ago, a new genetic disorder (OMIM # 615075) has been associated with loss-of-function variations in the CTNNB1 gene. The clinical features include a delayed psychomotor development usually leading to severe intellectual disability with or without autistic spectrum disorders, progressive spastic diplegia, and various visual defects. Among over 30 cases described worldwide, 2 were reported with an exaggerated startle response to sudden stimulus corresponding to a very rare neurological phenomenon called hyperekplexia. The investigators also have a 3rd patient carrying a CTNNB1 syndrome associated with hyperekplexia.


Description:

Hyperekplexia can impair daily life because the affected person will fall unexpectedly and stiffly, causing repeated head- or body- wounds. It may be treated empirically by various drugs. Hyperekplexia has so far not been associated with CTNNB1 variations. In this study, we aim to describe the prevalence and clinical characteristics of hyperekplexia in CTNNB1 syndrome carriers, in order to improve diagnosis and thus treatment. The investigators will recruit CTNNB1 subjects through health care providers and also by contacting the families through dedicated social media and databases. The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 10, 2022
Est. primary completion date December 10, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patient carrying a CTNNB1 syndrome showing an exaggerated startle response - child whose parents have signed a consent form to participate in the study Exclusion Criteria: - Absence of molecular diagnosis - Refusal to participate

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaire
The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).

Locations

Country Name City State
France Chu Saint-Etienne Saint-Étienne

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Saint Etienne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of hyperekplexia in CTNNB1 subjects Number of children with hyperekplexia and CTNNB1 syndrome on the day of filling in the questionnaire
Secondary Clinical features of hyperekplexia Clinical features (developmental, neurological, and visual disorders) of hyperekplexia in CTNNB1 syndrome on the day of filling in the questionnaire
See also
  Status Clinical Trial Phase
Terminated NCT01476514 - Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing N/A
Recruiting NCT05652101 - Hyperekplexia : Adaptative Skills and Neurodevelopmental Trajectory